Literature DB >> 10726647

Urine screening for gonococcal and chlamydial infections at community-based organizations in a high-morbidity area.

C A Jones1, R C Knaup, M Hayes, B P Stoner.   

Abstract

BACKGROUND: Increasing availability of urine testing for Neisseria gonorrhoeae (GC) and Chlamydia trachomatis (CT) offers expanded opportunities to collaborate with community-based organizations (CBOs) to screen high-risk populations for sexually transmitted diseases (STDs). GOAL: To determine the prevalence and correlates of genital tract gonococcal and chlamydial infection among CBO clients, and to assess the feasibility of implementing widespread community-based STD screening programs.
DESIGN: Free, voluntary, confidential first-catch urine screening was conducted at 20 CBOs serving disadvantaged populations in St. Louis, MO. Brief demographic, behavioral, and sexual contact data were obtained from all participants. Urine samples were tested by ligase chain reaction (LCR). Persons testing positive were promptly notified and directed to seek treatment.
RESULTS: A GC and/or CT infection was identified in 24 of 277 persons (8.7%) screened; 2 persons were infected with GC only, 17 with CT only, and 5 with GC and CT. Treatment was documented for 22 persons (91.7%) testing positive. The highest rates of infection were found at shelters (12.3%) and residence facilities (11.1%). Costs of screening were $38 per sample collected and $453 per case identified.
CONCLUSION: Community-based urine testing successfully identified GC and CT infections, and was well accepted by community members and CBOs. Community-based screening can significantly impact STD epidemiology by facilitating early detection, treatment, and interruption of transmission.

Entities:  

Mesh:

Year:  2000        PMID: 10726647     DOI: 10.1097/00007435-200003000-00005

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  9 in total

1.  Current Issues in Screening for Chlamydia trachomatis.

Authors:  Robert L. Cook; Lars ØStergaard
Journal:  Curr Infect Dis Rep       Date:  2003-04       Impact factor: 3.725

Review 2.  Surveillance and modelling of HIV, STI, and risk behaviours in concentrated HIV epidemics.

Authors:  S Mills; T Saidel; R Magnani; T Brown
Journal:  Sex Transm Infect       Date:  2004-12       Impact factor: 3.519

3.  Multicenter evaluation of the BDProbeTec ET System for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs, and male urethral swabs.

Authors:  B Van Der Pol; D V Ferrero; L Buck-Barrington; E Hook; C Lenderman; T Quinn; C A Gaydos; J Lovchik; J Schachter; J Moncada; G Hall; M J Tuohy; R B Jones
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

4.  Chlamydia trachomatis infections in multi-ethnic urban youth: a pilot combining STI health education and outreach testing in Rotterdam, Netherlands.

Authors:  H M Götz; I K Veldhuijzen; J M Ossewaarde; O de Zwart; J H Richardus
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

Review 5.  Traditional sexually transmitted disease prevention and control strategies: tailoring for African American communities.

Authors:  Roxanne Y Barrow; Cady Berkel; Lesley C Brooks; Samuel L Groseclose; David B Johnson; Jo A Valentine
Journal:  Sex Transm Dis       Date:  2008-12       Impact factor: 2.830

6.  Comparison of the APTIMA CT and GC assays with the APTIMA combo 2 assay, the Abbott LCx assay, and direct fluorescent-antibody and culture assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  B Boyadzhyan; T Yashina; J H Yatabe; M Patnaik; C S Hill
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

7.  A randomized trial of home versus clinic-based sexually transmitted disease screening among men.

Authors:  Mary M Reagan; Hanna Xu; Shirley L Shih; Gina M Secura; Jeffrey F Peipert
Journal:  Sex Transm Dis       Date:  2012-11       Impact factor: 2.830

8.  Performance of the APTIMA Combo 2 assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in female urine and endocervical swab specimens.

Authors:  C A Gaydos; T C Quinn; D Willis; A Weissfeld; E W Hook; D H Martin; D V Ferrero; J Schachter
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

9.  Evaluation of the Performance of the Cobas CT/NG Test for Use on the Cobas 6800/8800 Systems for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Male and Female Urogenital Samples.

Authors:  Barbara Van Der Pol; Kenneth Fife; Stephanie N Taylor; Melinda B Nye; Steven E Chavoustie; David L Eisenberg; LaShonda Crane; Gregory Hirsch; Rodney Arcenas; Elizabeth M Marlowe
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.